Sequential therapy with sorafenib and sunitinib in metastasized renal cell carcinoma (mRCC): a retrospective multi-center study and meta-analysis of available trials

被引：0
|
作者：
Liewen, H. [1 ]
Castonay, R. [1 ]
Haile, S. R. [2 ]
Cathomas, R. [3 ]
Rothermund, C. [4 ]
Siciliano, R. D. [5 ]
Stoll, S. [5 ]
Knuth, A. [1 ]
Renner, C. [1 ]
Samaras, P. [1 ]
Stenner, F. [1 ]
机构：
[1] Univ Spital Zurich, Zurich, Switzerland
[2] Univ Zurich, Inst Social & Prevent Med, Biostat Unit, CH-8006 Zurich, Switzerland
[3] Kantonsspital Graubunden, Chur, Switzerland
[4] Kantonsspital St Gallen, Dept Med Oncol, St Gallen, Switzerland
[5] Triemli City Hosp, Zurich, Switzerland
来源：
ONKOLOGIE | 2011年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：183 / 184
页数：2
相关论文
共 50 条
  • [1] SEQUENTIAL THERAPY WITH SUNITINIB-SORAFENIB IN METASTATIC RENAL CELL CARCINOMA (MRCC): PRELIMINARY RESULTS
    Condorelli, Rosaria
    Buscarino, Calogero
    Ferrau, Francesco
    Novello, Giuseppe
    Vigneri, Paolo
    Restuccia, Nunzio
    Banna, Giuseppe Luigi
    ANNALS OF ONCOLOGY, 2009, 20
  • [2] Sequential Therapy With Sorafenib and Sunitinib in Renal Cell Carcinoma
    Dudek, Arkadiusz Z.
    Zolnierek, Jakub
    Dham, Anu
    Lindgren, Bruce R.
    Szczylik, Cezary
    CANCER, 2009, 115 (01) : 61 - 67
  • [3] Sequential therapy with sorafenib and sunitinib in renal cell carcinoma
    Dham, A.
    Dudek, A. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis
    Wen, Tingyu
    Xiao, Hai
    Luo, Chao
    Huang, Li
    Xiong, Meimei
    ONCOTARGET, 2017, 8 (12) : 20441 - 20451
  • [5] A RETROSPECTIVE ANALYSIS OF SEQUENTIAL USE OF THE TYROSINE KINASE INHIBITORS (TKI) SORAFENIB (SOR) AND SUNITINIB (SUN) IN METASTATIC RENAL CELL CARCINOMA (mRCC)
    Calvani, N.
    Chetri, M. C.
    Cinefra, M.
    D'Amico, M.
    Fedele, P.
    Marino, M.
    Mazzoni, E.
    Nacci, A.
    Orlando, L.
    Rizzo, P.
    Schiavone, P.
    Sponziello, F.
    Cinieri, S.
    CANCER TREATMENT REVIEWS, 2010, 36 : S99 - S99
  • [6] SUNITINIB AND SORAFENIB THERAPY FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (mRCC): SAFETY PROFILE
    Massari, Francesco
    Cricca, Antonia
    Sperandi, Francesca
    Martoni, Andrea Angelo
    ANTICANCER RESEARCH, 2010, 30 (04) : 1379 - 1380
  • [7] RETROSPECTIVE ANALYSIS OF THE SEQUENTIAL USE OF SORAFENIB AND SUNITINIB IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)
    Porta, C.
    Procopio, G.
    Sabbatini, R.
    Bearz, A.
    Chiappino, I
    Imarisio, I.
    Guadalupi, V
    Paglino, C.
    Verzoni, E.
    Ferraris, E.
    Bajetta, E.
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (04) : 183 - 183
  • [8] Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): Analysis for safety and activity on sunitinib progressive pts
    Sepulveda, J.
    Maroto, P.
    Andres, R.
    Diaz Padilla, I.
    Coronado, C.
    DelaRosa, F.
    Castellano, D. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Response of renal lesions in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib - a single center retrospective analysis
    Seidel, C.
    Fenner, M.
    Reuter, C.
    Ivanyi, P.
    Ganser, A.
    Gruenwald, V.
    EJC SUPPLEMENTS, 2009, 7 (02): : 438 - 438
  • [10] A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma
    Stenner, Frank
    Chastonay, Rahel
    Liewen, Heike
    Haile, Sarah R.
    Cathomas, Richard
    Rothermundt, Christian
    Siciliano, Raffaele D.
    Stoll, Susanna
    Knuth, Alexander
    Buchler, Tomas
    Porta, Camillo
    Renner, Christoph
    Samaras, Panagiotis
    ONCOLOGY, 2012, 82 (06) : 333 - 340
12345